As reMYND alumnus and life-long supporter, it is an honour and pleasure for Diverge to take up a role as Strategy, Business & Client Development lead for its Contract Research Organisation. High on the agenda are the expansion to additional neurodegenerative disease areas and strengthening the client base in several upcoming R&D economies.
reMYND’s CRO helps its clients assess in-vivo characteristics, pharmacokinetics/dynamics and the effects of their experimental treatments against neurodegenerative diseases (Alzheimer, Parkinson, Huntington) in its proprietary mouse models.
We serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Asia-Pacific. We have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development and helped our clients to be the first to demonstrate the synergistic effect of a BACE inhibitor and an aBeta antibody, the effect of Tau antibody on aBeta, the effect of donepezil on brain Abeta and more!
The continuous availability of aged mice allows for a short response time and rapid study start. By contributing our extensive expertise and experience we are helping our clients to set up an optimal study design. The CRO offers a broad testing window for our portfolio of behavioral readouts in combination with all routes of administration, as well as immunohistochemical and biochemical read-outs, both in brain, cerebrospinal fluid and spinal cord.